D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The...